13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
28 檔
36.3%
In Q3 2025, Acuta Capital Partners, LLC's U.S. equity holdings reached a combined market value of $143.5M, distributed across 28 disclosed stock positions.
In Q3 2025, Acuta Capital Partners, LLC adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 17 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 14.08% | +0.07% | +14.81% | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 14.01% | — | -21.18% | |
| 3 | TRML | Tourmaline Bio Inc | Stock-Other | 13.27% | — | -5.37% | |
| 4 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 6.70% | +6.59% | — | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 5.74% | — | +4.11% | |
| 6 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 5.32% | -1.27% | +75.09% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.86% | +0.60% | -4.82% | |
| 8 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 4.68% | +0.61% | — | |
| 9 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.90% | -18.59% | EXIT | |
| 10 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.42% | — | -4.45% | |
| 11 | CMPX | Compass Therapeutics Inc | Stock-Other | 3.04% | -2.28% | — | |
| 12 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.72% | -0.13% | -32.85% | |
| 13 | SRZN | Surrozen Inc | Stock-Other | 2.38% | -0.44% | +4.95% | |
| 14 | ASND | Ascendis Pharma A/S | Stock-Other | 2.01% | — | -56.63% | |
| 15 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.93% | — | — | |
| 16 | OCS | Oculis Holding AG | Stock-Other | 1.85% | -1.86% | EXIT | |
| 17 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.54% | +1.27% | -6.35% | |
| 18 | COGT | Cogent Biosciences Inc | Stock-Other | 1.53% | — | — | |
| 19 | ZYME | Zymeworks Inc | Stock-Other | 1.41% | — | -4.20% | |
| 20 | VSTM | Verastem Inc | Stock-Other | 1.31% | — | -4.63% | |
| 21 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.02% | — | — | |
| 22 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.99% | -0.10% | — | |
| 23 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.57% | — | — | |
| 24 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.54% | — | -4.21% | |
| 25 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.49% | +0.14% | — | |
| 26 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.41% | -1.80% | EXIT | |
| 27 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.27% | -0.27% | EXIT | |
| 28 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +10.9% | -21.18% | Add |
| 2 | TRML | Tourmaline Bio Inc | +5.7% | -5.37% | Trim |
| 3 | OCUL | Ocular Therapeutix Inc | +3.7% | +14.81% | Trim |
| 4 | 430 | Terns Pharmaceuticals Inc | +2.9% | +8.39% | Add |
| 5 | DRUG | Bright Minds Biosciences Inc | +2.8% | +75.09% | Add |
| 6 | JAZZ | Jazz Pharmaceuticals plc | +2% | -4.45% | Add |
| 7 | ZYME | Zymeworks Inc | +0.5% | -4.20% | Add |
| 8 | SRZN | Surrozen Inc | +0.1% | +4.95% | Add |
| 9 | VSTM | Verastem Inc | +0.1% | -4.63% | Trim |
| 10 | ARGX | Argenx Se - Adr | 0% | -4.82% | Trim |
| 11 | NUVB-WS | Nuvation Bio Inc -cw27 | — | — | Unchanged |
| 12 | WHWK | Whitehawk Therapeutics Inc | -0.3% | — | Unchanged |
| 13 | OCS | Oculis Holding AG | -0.9% | -4.63% | Trim |
| 14 | PRAX | Praxis Precision Medicines I | -1.1% | -32.85% | Trim |
| 15 | ASND | Ascendis Pharma A/S | -2.2% | -56.63% | Trim |
| 16 | RVMD | Revolution Medicines Inc | -2.3% | -84.90% | Trim |
| 17 | INSM | Insmed Inc | -3.6% | +4.11% | Trim |
| 18 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 19 | TRVI | Trevi Therapeutics Inc | — | EXIT | Sold out |
| 20 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 21 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
| 22 | CMPX | Compass Therapeutics Inc | — | NEW | New buy |
| 23 | LQDA | Liquidia CORP | — | EXIT | Sold out |
| 24 | ✓ | Helix Acquisition CORP Ii | — | EXIT | Sold out |
| 25 | MRK | Merck & Co. Inc. | — | EXIT | Sold out |
| 26 | EWTX | Edgewise Therapeutics Inc | — | EXIT | Sold out |
| 27 | KRYS | Krystal Biotech Inc | — | NEW | New buy |
| 28 | MREO | Mereo Biopharma Group Pl-adr | — | EXIT | Sold out |
| 29 | TSHA | Taysha Gene Therapies Inc | — | NEW | New buy |
| 30 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 31 | ✓ | — | EXIT | Sold out | |
| 32 | GILD | Gilead Sciences Inc | — | EXIT | Sold out |
| 33 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 34 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 35 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 36 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 37 | RCKT | Rocket Pharmaceuticals Inc | — | EXIT | Sold out |
| 38 | INBX | Inhibrx Biosciences Inc | — | NEW | New buy |
| 39 | FULC | Fulcrum Therapeutics Inc | — | NEW | New buy |
| 40 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 41 | UNCY | Unicycive Therapeutics Inc | — | NEW | New buy |
| 42 | RAPP | Rapport Therapeutics Inc | — | EXIT | Sold out |
| 43 | FBRX | Forte Biosciences Inc | — | EXIT | Sold out |
| 44 | ARTV | Artiva Biotherapeutics Inc | — | EXIT | Sold out |
| 45 | ✓ | Enliven Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 28 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, CDTX, TRML) accounted for 36.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
AMLX
市值: $4.5M
Top Position Liquidated / Trimmed
ELVN
前期市值: $5.2M
During Q3 2025, Acuta Capital Partners, LLC's top holdings by market value included OCUL (14.1%)、CDTX (14.0%)、TRML (13.3%). The largest single position, OCUL, represented 14.1% of total portfolio value.
In Q3 2025, Acuta Capital Partners, LLC made 43 total portfolio adjustments, initiating 11 new buys, adding to 6 positions, trimming 9 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.